title: Sustained CD4 and CD8 lymphopenia after rituximab maintenance therapy following bendamustine and rituximab combination therapy for lymphoma.
authors.affiliation: a Department of Hematology , Hakodate Municipal Hospital , Hakodate , Japan.
authors.forename: Tsutsumi
authors.initials: T
authors.lastname: Yutaka
authors.affiliation: a Department of Hematology , Hakodate Municipal Hospital , Hakodate , Japan.
authors.forename: Shinichi
authors.initials: S
authors.lastname: Ito
authors.affiliation: a Department of Hematology , Hakodate Municipal Hospital , Hakodate , Japan.
authors.forename: Hiroyuki
authors.initials: H
authors.lastname: Ohigashi
authors.affiliation: a Department of Hematology , Hakodate Municipal Hospital , Hakodate , Japan.
authors.forename: Miyashita
authors.initials: M
authors.lastname: Naohiro
authors.affiliation: a Department of Hematology , Hakodate Municipal Hospital , Hakodate , Japan.
authors.forename: Joji
authors.initials: J
authors.lastname: Shimono
authors.affiliation: a Department of Hematology , Hakodate Municipal Hospital , Hakodate , Japan.
authors.forename: Shiratori
authors.initials: S
authors.lastname: Souichi
authors.affiliation: b Department of Hematology , Hokkaido University Graduate School of Medicine , Sapporo , Japan.
authors.forename: Takanori
authors.initials: T
authors.lastname: Teshima
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D000069461:Bendamustine Hydrochloride / Q000008:administration & dosage; D015496:CD4-Positive T-Lymphocytes; D018414:CD8-Positive T-Lymphocytes; D006801:Humans; D018655:Lymphocyte Count; D008223:Lymphoma / Q000150:complications* / Q000188:drug therapy*; D008231:Lymphopenia / Q000097:blood / Q000175:diagnosis / Q000209:etiology*; D060046:Maintenance Chemotherapy; D000069283:Rituximab / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*
chemical_list: D000069283:Rituximab; D000069461:Bendamustine Hydrochloride